Speaker illustration

Professor Kornelia Kotseva

Imperial College Healthcare NHS Trust, London (United Kingdom of Great Britain & Northern Ireland)

Professor Kornelia Kotseva, MD, PhD, FESC holds an academic appointment at the National Institute for Prevention and Cardiovascular Health, National University of Ireland – Galway, and a position as a Consultant Cardiologist at the Imperial College Healthcare NHS Trust, London, UK. She has been Chair of the Steering Committee of the European Society of Cardiology EUROASPIRE surveys, aiming to describe the risk factor management in patients with coronary disease and in people at high cardiovascular risk in Europe. Furthermore, she was a Principal Investigator and led several other European and UK studies. She has won numerous prestigious awards and has authored more than 250 publications. She led the module on Cardiovascular Risk Estimation and was involved in the development of the Master’s programme on Cardiovascular Health and Disease Prevention, Imperial College London. Her main research and clinical interest is primary and secondary prevention of cardiovascular disease.

Secondary Prevention and Rehabilitation 3

Event: ESC Preventive Cardiology 2023

Topic: Secondary Prevention

Session type: Abstract Sessions

Thumbnail

Essentials of sex and gender in cardiovascular disease prevention and management

Event: ESC Preventive Cardiology 2022

Topic: Cardiovascular Disease in Women

Session type: Special Session

Thumbnail

Lifestyle scores best

Event: ESC Congress 2019

Topic: Risk Factors and Prevention

Session type: Abstract Sessions

Thumbnail

Guidelines, clinical evidence and real life practice: how to find your way in managing patients at high cardiovascular risk?

Event: EuroPrevent 2019

Topic: Cardiovascular Risk Assessment

Session type: Symposium

Thumbnail

Cardiometabolic syndrome: challenges and advances

Event: ESC Congress 2016

Topic: Diabetes, dysglycaemia and metabolic syndrome

Session type: Symposium

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb